|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Sintilimab versus docetaxel as second-line treatment in advanced or metastatic squamous non-small-cell lung cancer:an open-label,randomized controlled phase 3 trial(ORIENT-3)显示文摘Background:Treatment options for Chinese patients with locally advanced or metastatic squamous-cell non-small-cell lung cancer(sqNSCLC)after failure of first-line chemotherapy are limited.This study(ORIENT-3)aimed to evaluate the efficacy and safety of sintilimab versus docetaxel as second-line treatment in patients with locally advanced or metastatic sqNSCLC.Methods:ORIENT-3 was an open-label,multicenter,randomized controlled phase 3 trial that recruited patients with stage IIIB/IIIC/IV sqNSCLC after failure with first-line platinum-based chemotherapy.Patients were randomized in a 1:1 ratio to receive either 200 mg of sintilimab or 75 mg/m^(2) of docetaxel intravenously every 3 weeks,stratified by the Eastern Cooperative Oncology Group performance status.The primary endpoint was overall survival(OS)in the full analysis set(FAS).Secondary endpoints included progression-free survival(PFS),objective response rate(ORR),disease control rate(DCR),duration of response(DoR)and safety.Results:Between August 25,2017,and November 7,2018,290 patients were randomized.For FAS,10 patients fromthe docetaxel armwere excluded.Themedian OS was 11.79(n=145;95%confidence interval[CI],10.28-15.57)months with sintilimab versus 8.25(n=135;95%CI,6.47-9.82)months with docetaxel(hazard ratio[HR]:0.74;95%CI,0.56-0.96;P=0.025).Sintilimab treatment significantly prolonged PFS(median 4.30 vs.2.79 months;HR:0.52;95%CI,0.39-0.68;P<0.001)and showed higher ORR(25.50%vs.2.20%,P<0.001)and DCR(65.50%vs.37.80%,P<0.001)than the docetaxel arm.The median DoRwas 12.45(95%CI,4.86-25.33)months in the sintilimab arm and 4.14(95%CI,1.41-7.23)months in the docetaxel arm(P=0.045).Treatment-related adverse events of grade≥3were reported in 26(18.1%)patients in the sintilimab arm and 47(36.2%)patients in the docetaxel arm.Exploratory biomarker analysis showed potential predictive values of expression levels of two transcription factors,including OVOL2(HR:0.35;P<0.001)and CTCF(HR:3.50;P<0.001),for sintilimab treatment.Conclusions:Compared with docetaxel,sintilimab significantly improved the OS,PFS,and ORR of Chinese patients with previously treated locally advanced or metastatic sqNSCLC. | Yuankai Shi Lin Wu Xinmin Yu Puyuan Xing Yan Wang Jianying Zhou Airong Wang Jianhua Shi Yi Hu Ziping Wang Guangyu An Yong Fang Sanyuan Sun Caicun Zhou Changli Wang Feng Ye Xingya Li Junye Wang Mengzhao Wang Yunpeng Liu Yanqiu Zhao Ying Yuan Jifeng Feng Zhendong Chen Jindong Shi Tao Sun Gang Wu Yongqian Shu Qisen Guo Yi Zhang Yong Song Shucai Zhang Yuan Chen Wei Li Hongrui Niu Wenwei Hu Lijun Wang Jianan Huang Yang Zhang Ying Cheng Zhengdong Wu Bo Peng Jiya Sun Christoph Mancao Yanqi Wang Luyao Sun | 2022 | Cancer Communications2022，42，12： | 8 |
| 2 | Ultrasound-triggered noninvasive regulation of blood glucose levels using microgels integrated with insulin nanocapsules显示文摘Diabetes is a serious public health problem affecting 422 million people worldwide. Traditional diabetes management often requires multiple daily insulin injections, associated with pain and inadequate glycemia control. Herein, we have developed an ultrasound-triggered insulin delivery system capable of pulsatile insulin release that can provide both long-term sustained and fast on-demand responses. In this system, insulin-loaded poly(lactic-co-glycolic acid) (PLGA) nanocapsules are encapsulated within chitosan microgels. The encapsulated insulin in nanocapsules can passively diffuse from the nanoparticle but remain restricted within the microgel. Upon ultrasound treatment, the stored insulin in microgels can be rapidly released to regulate blood glucose levels. In a chemically-induced type 1 diabetic mouse model, we demonstrated that this system, when activated by 30 s ultrasound administration, could effectively achieve glycemic control for up to one week in a noninvasive, localized, and pulsatile manner. | Jin Di Jicheng Yu Qun Wang Shanshan Yao Yanqi Ye Matthew Pless Yong Zhu Yun Jing Zhen Gu | 2017 | Nano Research2017，10，4： | 6 |
| 3 | Evaluation of human epidermal growth factor receptor 2 status of breast cancer using preoperative multidetector computed tomography with deep learning and handcrafted radiomics features显示文摘Objective:To evaluate the human epidermal growth factor receptor 2(HER2)status in patients with breast cancer using multidetector computed tomography(MDCT)-based handcrafted and deep radiomics features.Methods:This retrospective study enrolled 339 female patients(primary cohort,n=177;validation cohort,n=162)with pathologically confirmed invasive breast cancer.Handcrafted and deep radiomics features were extracted from the MDCT images during the arterial phase.After the feature selection procedures,handcrafted and deep radiomics signatures and the combined model were built using multivariate logistic regression analysis.Performance was assessed by measures of discrimination,calibration,and clinical usefulness in the primary cohort and validated in the validation cohort.Results:The handcrafted radiomics signature had a discriminative ability with a C-index of 0.739[95%confidence interval(95%CI):0.661-0.818]in the primary cohort and 0.695(95%CI:0.609-0.781)in the validation cohort.The deep radiomics signature also had a discriminative ability with a C-index of 0.760(95%CI:0.690-0.831)in the primary cohort and 0.777(95%CI:0.696-0.857)in the validation cohort.The combined model,which incorporated both the handcrafted and deep radiomics signatures,showed good discriminative ability with a C-index of 0.829(95%CI:0.767-0.890)in the primary cohort and 0.809(95%CI:0.740-0.879)in the validation cohort.Conclusions:Handcrafted and deep radiomics features from MDCT images were associated with HER2 status in patients with breast cancer.Thus,these features could provide complementary aid for the radiological evaluation of HER2 status in breast cancer. | Xiaojun Yang Lei Wu Ke Zhao Weitao Ye Weixiao Liu Yingyi Wang Jiao Li Hanxiao Li Xiaomei Huang Wen Zhang Yanqi Huang Xin Chen Su Yao Zaiyi Liu Changhong Liang | 2020 | Chinese Journal of Cancer Research2020，32，2： | 4 |
| 4 | Shape-controlled synthesis of liquid metal nanodroplets for photothermal therapy显示文摘The capping agents for liquid metal (LM) nanodroplets in aqueous solutions are restricted to thiol-containing and positively-charged molecules or macromolecules.However,both thiolate-metal complex and electrostatic interaction are liable to detachment upon strong mechanical forces such as sonication,leading to limited stability and applications.To address this,we utilized ultrasmall water soluble melanin nanoparticles (MNPs) as the capping agent,which exhibited strong metal binding capability with the oxide layer of gallium based LMs and resulted in enhanced stability.Interestingly,shape-controlled synthesis of LM nanodroplets can be achieved by the incorporation of MNPs.Various EGaln nanostructures including nanorice,nanosphere and nanorod were obtained by simply tuning the feed ratio,sonication time,and suspension temperature.Among these shapes,EGaln nanorice has the best photothermal conversion efficiency,which could be leveraged for photothermal therapy. | Junjie Yan Xudong Zhang Yang Liu Yanqi Ye Jicheng Yu Qian Chen Jinqiang Wang Yuqi Zhang Quanyin Hu Yang Kang Min Yang Zhen Gu | 2019 | Nano Research2019，12，6： | 2 |
| 5 | Simultaneous removal of ammonia, P and COD from anaerobically digested piggery wastewater using an integrated process of chemical precipitation and air stripping显示文摘 | Xuejun Quan Changying Ye Yanqi Xiong Jinxin Xiang Fuping Wang | 2010 | Journal of Hazardous Materials2010，，1： | 2 |
| 6 | Simultaneous removal of ammonia, P and COD from anaerobically digested piggery wastewater using an integrated process of chemical precipitation and air stripping 显示文摘 | Quan Xuejun Ye Changying Xiong Yanqi | 2010 | Journal of Hazardous Materials2010，178，13： | 1 |
| 7 | Preparation and investigation of a novel iodine-based visible polyvinyl alcohol embolization material显示文摘Polyvinyl alcohol(PVA) embolization particles, currently used in clinical practice, have good expansibility and are capable of permanent embolization. However, the lack of adhesion of embolization particles contributes to facilitated recanalization after embolization, while the lack of visualization facilitates misembolization. At present, embolization materials with good expansion, adhesion, and visualization potential are urgently required in clinical practice. Here, we report the development of PVA/gelatin/iohexol(I) fiber blocks as a novel embolization material for liver embolization in rats. In our work, electrospun PVA/gelatin/I nanofibrous mats were first prepared, homogenized, centrifuged in a gradient manner, and freeze-dried to obtain fiber blocks(fiber diameter =296.2 ± 74.23 nm, length 99.6 ± 17.0 μm × width 46.9 ± 13.3 μm). The fiber blocks exhibited excellent cytocompatibility and hemocompatibility. Fiber blocks with a PVA/gelatin/I mass ratio of 8:2:10 were selected due to their excellent expansibility and adhesive properties. The PVA/gelatin/I fiber blocks display excellent liver embolic effects and computed tomography(CT) imaging potential due to a combination of the following characteristics: expansibility of PVA and gelatin, adhesive property of gelatin, and CT imaging potential of I. The developed fiber block material is an embolic material that may potentially be used in interventional medicine. | Yupeng Yang Rui Yang Beilei Zhang Ye Tian Yanqi Lu Xiao An Xiangyang Shi | 2022 | Journal of Interventional Medicine2022，5，2： | 1 |
| 8 | Management of pulmonary nodules in non-high-risk population:initial evidence from a real-world prospective cohort study in China显示文摘To the Editor:Lung cancer continues to be the most common cause of tumor-related death globally.Screening by low-dose computed tomography(CT)has been proven to greatly reduce the mortality of lung cancer patients.Although the recommended screened population varies among different guidelines,elderly smokers are always the most important subjects.However,a substantial group of lung cancer patients has been found to be young without tobacco consumptionJ11 Non-smoking lung cancer was even considered to be an independent disease and the seventh leading cause of cancer mortality. | Jing Ren Feng Chen Qing Liu Yongzhao Zhou Yue Cheng Panwen Tian Ye Wang Yalun Li Yanqi He Dan Liu Bojiang Chen Weimin Li | 2022 | Chinese Medical Journal2022，，8： | 1 |
| 9 | Smart nanoparticles for cancer therapy显示文摘Smart nanoparticles,which can respond to biological cues or be guided by them,are emerging as a promising drug delivery platform for precise cancer treatment.The field of oncology,nanotechnology,and biomedicine has witnessed rapid progress,leading to innovative developments in smart nanoparticles for safer and more effective cancer therapy.In this review,we will highlight recent advancements in smart nanoparticles,including polymeric nanoparticles,dendrimers,micelles,liposomes,protein nanoparticles,cell membrane nanoparticles,mesoporous silica nanoparticles,gold nanoparticles,iron oxide nanoparticles,quantum dots,carbon nanotubes,black phosphorus,MOF nanoparticles,and others.We will focus on their classification,structures,synthesis,and intelligent features.These smart nanoparticles possess the ability to respond to various external and internal stimuli,such as enzymes,pH,temperature,optics,and magnetism,making them intelligent systems.Additionally,this review will explore the latest studies on tumor targeting by functionalizing the surfaces of smart nanoparticles with tumor-specific ligands like antibodies,peptides,transferrin,and folic acid.We will also summarize different types of drug delivery options,including small molecules,peptides,proteins,nucleic acids,and even living cells,for their potential use in cancer therapy.While the potential of smart nanoparticles is promising,we will also acknowledge the challenges and clinical prospects associated with their use.Finally,we will propose a blueprint that involves the use of artificial intelligence-powered nanoparticles in cancer treatment applications.By harnessing the potential of smart nanoparticles,this review aims to usher in a new era of precise and personalized cancer therapy,providing patients with individualized treatment options. | Leming Sun Hongmei Liu Yanqi Ye Yang Lei Rehmat Islam Sumin Tan Rongsheng Tong Yang-Bao Miao Lulu Cai | 2023 | Signal Transduction and Targeted Therapy2023，8，12： | 0 |
| 10 | Above the dose threshold:a simple way to improve the delivery efficiency of nanomedicine显示文摘Recently,a paper by Warren Chan et al.published in Nature Materials,discovered a simple way to improve the tumor delivery efficiency by reaching a nanomedicine dose above a threshold.1 As the largest organ of the reticuloendothelial system,the liver takes up majority of nanomedicine after ingestion.2 This dose threshold is based on the kinetic balance between the uptake of nanomedicine in the liver and the absorption in the tumor,which is related to the number of receptors and binding sites available on Kupffer cells residing in the liver(Fig.1).A dose exceeding the effective binding site threshold overwhelmed the Kupffer cells,therefore it can reduce the liver clearance of nanomedicine and prolong the circulation. | Lei Yang Yanqi Ye Lulu Cai | 2020 | Signal Transduction and Targeted Therapy2020，5，1： | 0 |
| 11 | Supramolecular attack particle:the way cytotoxic T lymphocytes kill target cells显示文摘A very recent study by Bálint et al.published in Science deciphered in detail how cytotoxic T lymphocytes(CTLs)kill target cells.1 They found that perforin and pellet enzyme—the cytotoxic substances in CTLs—combined and assembled into supramolecular attack particles(SMAPs).The SMAPs were subsequently released toward the cell membrane of the target cell.The shell of SMAP was rich in glycoproteins that enabled its stability to maintain the cell-killing activity for hours,in which the thrombospondin-1(TSP-1)was critical(Fig.1). | Jiaqi Liu Yanqi Ye Lulu Cai | 2020 | Signal Transduction and Targeted Therapy2020，5，1： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员